The global stem cell manufacturing market was valued at USD 12.44 billion in 2022. The market size is further estimated to grow and reach USD 22.21 billion by 2028 from USD 13.7 billion in 2023, registering a CAGR of 10.14% between 2023 to 2028.
Impact of COVID-19 on Stem Cell Manufacturing Market:
The COVID-19 pandemic has shown a mixed impact on the global stem cell manufacturing market. On one side, the disruptions in the global supply chains caused by the COVID-19 pandemic affected the availability and timely delivery of critical supplies, leading to operational challenges for stem cell manufacturing facilities. The COVID-19 pandemic also caused delays in the clinical trial activities involved in stem cell therapies. It has become difficult to recruit and monitor participants during the COVID-19 pandemic due to the restrictions imposed such as lockdowns, travel restrictions and social distancing. The COVID-19 pandemic has also affected the funding opportunities for stem cell manufacturing companies. The COVID-19 pandemic has created an immediate need to develop and produce vaccines to fight the novel coronavirus. Several pharmaceutical and biotechnological companies have shifted their resources, funding and manufacturing capacities towards the development and production of vaccines for COVID-19 and given less importance to other research areas including stem cell therapies. Such factors have impacted the stem cell manufacturing market during the COVID-19 pandemic. On the other side, the focus on regenerative medicine and the potential of stem cell therapies has increased during the COVID-19 pandemic as several governments worldwide have realized the importance of developing innovative treatments for various diseases and conditions, which favors the stem cell manufacturing market. Likewise, the global stem cell manufacturing market has been impacted positively and negatively by the COVID-19 pandemic. However, the market is expected to register a healthy CAGR during the forecast period.
MARKET DRIVERS:
The growing patient population with chronic diseases majorly drives the stem cell manufacturing market growth. The prevalence of chronic diseases is growing rapidly worldwide. As per the data published by the American Hospital Association (AHA), an estimated 133 million Americans suffer from at least one chronic disease. This number is predicted to touch 170 million by 2030. The growing number of people suffering from chronic diseases such as cancer, diabetes, cardiovascular disorders and neurological conditions has accelerated the need for innovative treatments including stem cell therapies. This trend is likely to continue in the coming years and contribute to market growth.
The growing use of stem cells in regenerative medicine that results in the potential to repair and regenerate damaged tissues and organs further boosts the growth rate of the stem cell manufacturing market. Ongoing advancements in stem cell research are projected to result in the development of new stem cell manufacturing techniques and therapies and this factor is predicted to favor market growth during the forecast period. The supportive regulatory environment for stem cell manufacturing fuels the market’s growth rate. The regulatory bodies of several countries have established favorable policies for stem cell therapies and support the development and commercialization of stem cell therapies. Such actions resulted in increased investments in the stem cell manufacturing market in the recent past and the same is expected to continue in the coming years.
The surge in private and public funding for stem cell research and development, the growing aging population who are more prone to chronic diseases and age-related conditions, the availability of manufacturing technologies, such as automated systems, bioreactors and 3D cell culture techniques in the developed and developing countries, an increasing number of collaborations and partnerships between academia, research institutions and market participants promote the growth of the stem cell manufacturing market. The growing number of investments in the biotechnology sector, the wide range of therapeutic areas of stem cells such as oncology, orthopedics, cardiovascular diseases, neurological disorders and autoimmune conditions, the rising awareness and acceptance of stem cell therapies by the patients and healthcare professionals, research grants to support stem cell research and manufacturing by the governmental organizations further propel the stem cell manufacturing market growth.
MARKET RESTRAINTS:
Rigorous regulations and guidelines imposed by health authorities to ensure patient safety and product efficacy of stem cell therapies are one of the key factors hampering the market growth. Ethical debates and moral concerns regarding the use of embryonic stem cells, high costs associated with stem cell manufacturing, lack of standardization across different laboratories and manufacturing facilities and lack of infrastructure required for large-scale stem cell manufacturing in some countries hinder market growth. Limited clinical evidence and supply chain challenges further impede the market growth.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2022 to 2028 |
|
Base Year |
2022 |
|
Forecast Period |
2023 to 2028 |
|
Segments Covered |
By Product, Application, End-User, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa |
This research report on the global stem cell manufacturing market has been segmented and sub-segmented based on the product, application, end-user and region.
Global Stem Cell Manufacturing Market - By Product:
Based on product, the consumables segment had the leading share of the global market in 2022 and is expected to witness a healthy CAGR during the forecast period. The growing demand for stem cell therapies and regenerative medicine applications, increasing investments in stem cell research and development, advancements in stem cell culture and expansion technologies drive segmental growth. The rise of 3D cell culture techniques that require a range of consumables and the rapid adoption of automated and standardized manufacturing processes further boosts the segment’s growth rate.
The stem cell lines segment is predicted to grow at a promising CAGR during the forecast period due to the growing number of advancements in stem cell research and development leading to the discovery of new stem cell lines, rising demand for stem cell lines for research purposes and growing use of stem cell lines for drug discovery and toxicity testing. The potential of stem cell lines for developing personalized medicine and cell-based therapies and rising investments in stem cell research and development by academic and research institutions, as well as biopharmaceutical companies further contribute to the segmental growth.
The instruments segment had a considerable share of the worldwide market in 2022 and is predicted to grow steadily during the forecast period owing to factors such as the growing number of advancements in stem cell processing technologies and equipment, rising demand for automated and high throughput manufacturing processes and increasing emphasis on quality control and regulatory compliance.
Global Stem Cell Manufacturing Market - By Application:
Based on application, the research segment led the market in 2022 and is expected to grow healthy during the forecast period. The growing investments in stem cell research by government and private organizations for R&D, rising demand for stem cells for drug discovery and toxicity testing and increasing number of advancements in stem cell research technologies and techniques primarily drive the segmental growth. The potential of stem cells for developing regenerative medicine applications and the rising availability of stem cell lines and culture media for research purposes further accelerate the growth rate of the segment.
The clinical segment had the second largest share of the worldwide market in 2022 and is predicted to grow at a promising CAGR during the forecast period owing to the rising prevalence of chronic diseases, such as diabetes, cancer, and cardiovascular diseases, growing demand for regenerative medicine and cell-based therapies and increasing applications of stem cells in various fields, such as orthopedics, neurology and ophthalmology contribute to the segmental growth.
The cell & tissue banking segment is estimated to grow at a steady CAGR during the forecast period due to factors such as the rising demand for stem cell and tissue banking services, rapid adoption of cord blood banking for neonatal stem cell collection, increasing number of advancements in stem cell and tissue preservation techniques and equipment. The rising awareness of the potential of stem cells and tissues for regenerative medicine applications and the potential of stem cells and tissues for developing personalized medicine and cell-based therapies further propel segmental growth.
Global Stem Cell Manufacturing Market - By End-User:
Based on end-user, the pharmaceutical & biotechnology companies segment is predicted to lead the market during the forecast period. The growing investments in stem cell research and development by pharmaceutical and biotechnology companies, increasing focus on developing novel stem cell-based therapies and regenerative medicine products and rising number of collaborations and partnerships between pharmaceutical companies and stem cell manufacturing firms primarily drive the segmental growth.
Global Stem Cell Manufacturing Market - By Region:
North America captured the largest share of the global market in 2022. North America is predicted to retain the leading position in the global market throughout the forecast period. The well-established and technologically advanced healthcare infrastructure, and strong investments in stem cell research and development by pharmaceutical companies, biotechnology firms and academic institutions primarily drive the North American market growth. Favorable regulations from the governments of North America and supportive policies for stem cell research and clinical trials, the growing prevalence of chronic diseases and the high demand for advanced therapies fuel the growth of the stem cell manufacturing market in this region. The U.S. was the largest contributor to the North American market in 2022 and is predicted to grow at a promising CAGR during the forecast period. The substantial investments for the R&D of stem cell therapies in the U.S., the presence of advanced healthcare infrastructure, strong regulatory frameworks and a robust biopharmaceutical industry contribute to the U.S. market growth.
Europe held a notable share of the global market in 2022 and is predicted to grow substantially during the forecast period. The robust regulatory framework that facilitates the R&D of stem cells, the increasing number of initiatives and funding from the European governments for stem cell research projects and clinical trials and collaborations between academic institutions, research organizations, and industry players propel the European market growth. The rapid adoption of regenerative medicine and stem cell-based treatments in European countries, technological advancements and the availability of skilled workforce in the European region further drive the market growth in Europe. Germany, the UK, and Switzerland accounted for the major share of the European market in 2022. The trend is likely to repeat throughout the forecast period due to the supportive government regulations and funding for stem cell research and clinical trials.
APAC was the third-largest regional market for stem cell manufacturing worldwide in 2022 and is predicted to register the fastest CAGR during the forecast period. The large patient population, increasing healthcare expenditure and growing emphasis on regenerative medicine primarily drive the APAC market growth. The growing number of initiatives in terms of funding and regulatory support from the governments of APAC countries to promote the R&D of stem cells and an increasing number of investments in healthcare infrastructure and stem cell manufacturing facilities further drive the market expansion in the Asia-Pacific region. The rising awareness and acceptance of stem cell therapies among healthcare professionals and patients in the Asia-Pacific region further contribute to the regional market growth. Japan followed by China held the major share of the APAC market in 2022.
Latin America is predicted to witness healthy growth during the forecast period due to factors such as the growing awareness about regenerative medicine and the potential of stem cell therapies among healthcare professionals and patients, rising prevalence of chronic diseases and increasing demand for advanced treatment options. Mexico followed by Brazil led the market in Latin America in 2022.
MEA is still in the early stages of developing the stem cell manufacturing market. However, this regional market is predicted to grow steadily during the forecast period due to the growing investments for healthcare infrastructure, research, and development activities in countries like the United Arab Emirates (UAE) and Saudi Arabia and an increasing number of government initiatives to attract international stem cell manufacturing companies to establish facilities in the Middle East and Africa.
KEY MARKET PLAYERS:
Thermo Fisher Scientific Inc., Lonza Group Ltd., Merck KGaA (MilliporeSigma), STEMCELL Technologies Inc., Fujifilm Holdings Corporation (CDI Bioscience), Takara Bio Inc., Cellular Dynamics International, GE Healthcare Life Sciences, Sartorius AG and Charles River Laboratories International Inc. are a few of the noteworthy companies in the global stem cell manufacturing market.
Frequently Asked Questions
The global stem cell manufacturing market is predicted to be valued at USD 13.7 billion in 2023.
The dominating region in the stem cell manufacturing market can vary, but North America and Europe have historically been prominent due to their advanced healthcare infrastructure, significant investments in research and development, supportive regulations, and strong presence of pharmaceutical and biotechnology companies.
Some of the challenges in the stem cell manufacturing market include stringent regulatory requirements, ethical considerations surrounding the use of certain types of stem cells, complexities in scaling up stem cell production, ensuring product quality and consistency, high manufacturing costs, and the need for robust infrastructure and skilled personnel for manufacturing and processing stem cells.
Emerging trends in the stem cell manufacturing market include the development of novel technologies for efficient and scalable stem cell culture and differentiation, the use of induced pluripotent stem cells (iPSCs) for disease modeling and drug screening, automation and robotics for streamlined manufacturing processes, increasing adoption of 3D bioprinting for tissue engineering, and the exploration of novel sources of stem cells, such as mesenchymal stem cells derived from umbilical cord tissue or menstrual blood.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region